Saltar al contenido
Merck
  • Increased antioxidant defense mechanism in human adventitia-derived progenitor cells is associated with therapeutic benefit in ischemia.

Increased antioxidant defense mechanism in human adventitia-derived progenitor cells is associated with therapeutic benefit in ischemia.

Antioxidants & redox signaling (2014-02-12)
Dominga Iacobazzi, Giuseppe Mangialardi, Miriam Gubernator, Manuela Hofner, Matthias Wielscher, Klemens Vierlinger, Carlotta Reni, Atsuhiko Oikawa, Gaia Spinetti, Rosa Vono, Elena Sangalli, Monica Montagnani, Paolo Madeddu
RESUMEN

Vascular wall-resident progenitor cells hold great promise for cardiovascular regenerative therapy. This study evaluates the impact of oxidative stress on the viability and functionality of adventitia-derived progenitor cells (APCs) from vein remnants of coronary artery bypass graft (CABG) surgery. We also investigated the antioxidant enzymes implicated in the resistance of APCs to oxidative stress-induced damage and the effect of interfering with one of them, the extracellular superoxide dismutase (EC-SOD/SOD3), on APC therapeutic action in a model of peripheral ischemia. After exposure to hydrogen peroxide, APCs undergo apoptosis to a smaller extent than endothelial cells (ECs). This was attributed to up-regulation of antioxidant enzymes, especially SODs and catalase. Pharmacological inhibition of SODs increases reactive oxygen species (ROS) levels in APCs and impairs their survival. Likewise, APC differentiation results in SOD down-regulation and ROS-induced apoptosis. Oxidative stress increases APC migratory activity, while being inhibitory for ECs. In addition, oxidative stress does not impair APC capacity to promote angiogenesis in vitro. In a mouse limb ischemia model, an injection of naïve APCs, but not SOD3-silenced APCs, helps perfusion recovery and neovascularization, thus underlining the importance of this soluble isoform in protection from ischemia. This study newly demonstrates that APCs are endowed with enhanced detoxifier and antioxidant systems and that SOD3 plays an important role in their therapeutic activity in ischemia. APCs from vein remnants of CABG patients express antioxidant defense mechanisms, which enable them to resist stress. These properties highlight the potential of APCs in cardiovascular regenerative medicine.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Dexametasona, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Anticuerpo anti-fosfo-histona H2A.X (Ser139), clon JBW301, clone JBW301, Upstate®, from mouse
Sigma-Aldrich
Dexametasona, ≥98% (HPLC), powder
Millipore
Peróxido de hidrógeno solution, 3%, suitable for microbiology
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
Hydroxyurea, 98%, powder
Sigma-Aldrich
Peróxido de hidrógeno solution, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
Dexametasona, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Supelco
Dexametasona, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Dexametasona, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Supelco
Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Dexametasona, meets USP testing specifications
Sigma-Aldrich
Dexametasona, tested according to Ph. Eur.
Dexametasona, European Pharmacopoeia (EP) Reference Standard
USP
Indomethacin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Dexametasona, European Pharmacopoeia (EP) Reference Standard
Dexametasona, European Pharmacopoeia (EP) Reference Standard